Rochester, NY 9/1/2009 12:13:20 PM
ACADIA Pharmaceuticals, Inc. ACAD, Down 2.34% after market closed
ACADIA Pharmaceuticals, Inc.
Acadia Pharmaceuticals said it is likely to exercise an option to co-market its psychosis drug in the United States, and that the experimental product has strong sales potential. Acadia in May announced a deal under which Biovail Corp will help develop its drug, pimavanserin, and sell it in North America, with Acadia having an option to co-market the product in the same market.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to BOTTOM of this page for free stock alerts, or visit our site.
Last Trade: 5.84
Day's Range: 5.80 - 5.99
52wk Range: 0.72 - 6.60
Change: Down 0.14 (2.34%)
Volume: 979,026
Avg Vol (3m): 1,267,500
About ACADIA Pharmaceuticals, Inc.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson’s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company’s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.
